  --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Resource Table.                         
  --------------------------------------- ----------------------------------------------------------------------------------------------------------------------
  Unique stem cell line identifier        CDMLi002-A

  Alternative name(s) of stem cell line   FCP351G

  Institution                             McGovern Medical School, The University of Texas Health Science Center Houston

  Contact information of distributor      Dung-Fang Lee <dung-fang.lee@uth.tmc.edu>

  Type of cell line                       iPSCs

  Origin                                  Human

  Additional origin info                  Age: 24 years\
                                          Sex: F\
                                          Ethnicity if known: not Hispanic, White

                                          Ethnicity if known: not Hispanic, White

  Cell source                             fibroblast

  Clonality                               clonal

  Method of reprogramming                 Sendai virus

  Genetic modification                    N/A

  Type of modification                    Germline mutation

  Associated disease                      Rothmund-Thomson syndrome

  Gene/locus                              *RECQL4* (c.1878 + 32_1878 + 55del24)/ 8q24.3

  Method of modification                  N/A

  Name of transgene or resistance         N/A

  Inducible/constitutive system           N/A

  Date archived/stock date                3/31/2018

  Cell line repository/bank               N/A

  Ethical approval                        The Molecular Basis of Familial Cancer Predisposition Syndromes (IRB\# H-7207) provide by Baylor College of Medicine
  --------------------------------------------------------------------------------------------------------------------------------------------------------------

Resource utility {#S1}
================

We have generated an iPSC line with a heterozygous *RECQL4* (c.1878 + 32_1878 + 55del24) mutation. This iPSC line will be useful to study the effects of aberrant RECQL4 protein on genomic stability.

Resource details {#S2}
================

RECQL4, one of five human RecQ DNA helicases, is known as a guardian of the genome due to its function in multiple DNA metabolic processes, including DNA replication, recombination and repair ([@R4]; [@R2]). Compound heterozygous or homozygous mutations in the *RECQL4* gene are responsible for the majority of cases of Rothmund-Thomson syndrome (RTS), an autosomal recessive disorder characterized by multiple clinical features including a poikilodermatous skin rash, small stature, skeletal dysplasias, and a striking risk for developing osteosarcoma ([@R4]; [@R2]). Here we have reprogrammed fibroblasts from an RTS heterozygous carrier of *RECQL4* mutation c.1878 + 32_1878 + 55del24, a 24 base pair deletion in intron 11 of the *RECQL4* gene ([Fig. 1A](#F1){ref-type="fig"}). This mutation results in a shortened intron and has been shown to cause aberrant splicing leading to exon skipping ([@R5]; [@R1]). The resource we describe here will be useful in characterizing the role of RECQL4 in DNA damage repair and replication and provides a valuable tool for investigating the pathogenesis of osteosarcoma.

Fibroblasts were isolated from a punch biopsy taken from the arm of an individual with a heterozygous *RECQL4* (c.1878 + 32_1878 + 55del24) mutation. Primary fibroblasts were reprogrammed by Yamanaka four factors OCT4, SOX2, KLF4 and MYC using CytoTune-iPS Sendai Reprogramming kit. The emerged iPS clones were picked and cultured for approximately 15 passages. The iPS clone FCP351G exhibits hESC morphology which is evident by cell clusters with a dense, domed center and well-defined borders ([Fig. 1B](#F1){ref-type="fig"}, left panel, Scale bar, 250 μm). PCR detection of exogenous *OCT4, SOX2, KLF4* and *MYC* in FCP351G iPSC line verified loss of Sendai virus and transgenes ([Fig. 1C](#F1){ref-type="fig"}). PCR-based mycoplasma detection assay further validates FCP351G iPSCs are free of mycoplasma ([Fig. 1D](#F1){ref-type="fig"}). The short tandem repeat (STR) profile of FCP351G iPSCs were identical to that of parental FCP351 fibroblasts (data available upon request). Immunofluorescence staining of FCP351G iPSCs demonstrated ubiquitous expression of pluripotency transcription factor NANOG, hESC surface markers SSEA-4 and TRA-1-81 ([Fig. 1E](#F1){ref-type="fig"}, Scale bar, 75 μm) and alkaline phosphatase ([Fig. 1B](#F1){ref-type="fig"}, right panel, Scale bar, 100 μ:m). Examination of pluripotent gene expression by qRT-PCR showed that FCP351G iPSCs express pluripotency gene *NANOG, OCT4, SOX2, DPPA4, REX1* and *TERT* at a level equal to or greater than H1 hESCs, whereas FCP351 fibroblasts do not express these genes ([Fig. 1F](#F1){ref-type="fig"}) Higher *SOX2* and *TERT* mRNAs in FCP351G iPSCs may reult from RECQL4 mutation-induced gene up-regulation. G-band karyotype analysis confirmed the normal karyotype of the FCP351G iPSCs ([Fig. 1G](#F1){ref-type="fig"}). Teratoma assay indicates that FCP351 iPSCs are capable of differentiation to three germ layers including epithelium (endoderm), cartilage (mesoderm), and melanin (ectoderm) ([Fig. 1H](#F1){ref-type="fig"}), confirming their pluripotency. The characterization of the FCP351G iPSC line is summarized in [Table 1](#T2){ref-type="table"}.

In summary, FCP351G iPSCs are pluripotent and demonstrate a normal karyotype. FCP351G iPSCs provide a valuable cell resource to study RECQL4 function.

Materials and methods {#S3}
=====================

Cell culture {#S4}
------------

Fibroblasts were cultured in DMEM/F12 (Corning) supplemented with Glutamax (Thermo Fisher) and 10% FBS (GenDEPOT) at 37 °C with 5% CO~2~ after thawing until the cells were confluent. Cells were then passaged to six well plates, where they were grown to approximately 90% confluence. Cells were then reprogrammed with OCT4, SOX2, KLF4, and MYC using the CytoTune iPS 2.0 Sendai reprogramming kit (Life Technologies) according to manufacturer\'s instructions. Clones were picked and seeded in 96-well plates coated with Matrigel (Corning) using hESC medium supplemented with ROCK inhibitor Thiazovivin (Millipore). After one day of culture, the medium was replaced with StemMACS iPS-Brew XF media (Miltenyi Biotech). Following growth, these clones were passaged to a six well plate and cultured in the same manner for approximately 15 passages to ensure the removal of Sendai viruses.

PCR, sequencing, and STR {#S5}
------------------------

Genomic DNA was isolated from one 10 cm dish of 80% confluent iPSCs according to protocol using the PureLink DNA Isolation kit (Invitrogen). PCR was performed using primers listed in [Table 2](#T3){ref-type="table"} and OneTaq polymerase (New England Biolabs). PCR reaction was performed according to the following protocol: 94 °C for 1 min; 35 cycles of reaction: 94 °C for 30 s, 56 °C for 45 s and 68 °C for 1 min; and 68 °C for 5 min on a Biometra TRIO Thermal Cycler (Analytik Jena). Sanger sequencing was done by Eton Bioscience (San Diego, California). STR DNA fingerprinting was done by the CCSG-funded Characterized Cell Line Core Facility at the University of Texas M.D. Anderson Cancer Center. The STRs at 14 loci (AMEL, CSF1PO, D13S317, D16S539, D18S51, D21S11, D3S1358, D5S818, D7S820, D8S1179, FGA, TH01, TPOX and vWA) were assessed in the FCP351G iPSC line and original FCP351 fibroblast.

qRT-PCR {#S6}
-------

RNA was isolated from cells grown to 85% confluency in 6 well culture dish using Trizol (Life Technologies) according to manufacturer\'s instructions. 4 μg of RNA was used to make cDNA according to the reverse transcriptase protocol using iScript Reverse Transcription Supermix (BioRad). qPCR was then performed using primers described in [Table 2](#T3){ref-type="table"} according to the protocol using iQ SYBR Green Supermix (Biorad) on a CFX96 machine (Bio-Rad). The reaction was performed according to the following parameters: 50 °C for 10 min, 95 °C for 5 min, 40 cycle of 95 °C for 10 s and 60 °C for 30 s, and 95 °C for 10 min. Results were calculated using the ΔΔCT method and were normalized to GAPDH expression and are displayed relative to hESC H1.

Mycoplasma testing {#S7}
------------------

Mycoplasma detection was performed using PCR Mycoplasma Detection Kit (Applied Biological Materials Inc) according to the manufacturer\'s instructions.

Karyotyping {#S8}
-----------

The cultures were harvested and G-banded using standard protocols. Clonal chromosomal changes identified by G-banding were described according to an International System for Human Cytogenetic Nomenclature ISCN ([@R3].). Twenty metaphase chromosome spreads at 400 band resolution were analyzed.

Immunofluorescent staining {#S9}
--------------------------

iPSCs were grown to 70% confluence in 12 well plates, then fixed with 4% paraformaldehyde (Affymatrix) for 10 min. Cells were then washed 2 × 500 μL in wash buffer (PBS with 1% BSA (Fisher Scientific), followed by blocking with PBS with 10% donkey serum (Jackson ImmunoResearch Labs), 1% BSA, 0.3% Triton X-100 (Sigma) for 45 min. Cells were then incubated with primary antibody diluted in dilution buffer (PBS with 1%BSA, 1% donkey serum, 0.3% Triton X-100, and 0.01% sodium azide (Sigma) at 4 °C overnight gently rocking. Cells were then washed twice. Where appropriate, secondary antibody was diluted in dilution buffer, then added to cells and incubated for 1 h at room temperature protected from light. This was followed by 2 more washes, then counterstain with DAPI diluted in dilution buffer. Cells were finally washed 2 times, then stored in PBS for visualization.

Alkaline phosphatase staining {#S10}
-----------------------------

iPSCs were grown to 70% confluence in 12 well plates, then fixed and stained using the Alkaline Phosphatase Staining Kit II (Stemgent) according to manufacturer\'s instructions.

Teratoma assay {#S11}
--------------

Cells were grown in 10 cm dishes to 80% confluence. Cells were dissociated from the dish, then resuspended in phenol red-free Matrigel (Corning cat\#354262). Immunodeficient NOD SCID mice (Charles River Laboratories) were injected subcutaneously with 2 × 10^7^ cells in each flank and observed for palpable teratoma formation. After approximately 6 weeks, teratomas were excised then fixed in 10% formalin (Sigma). Histology was performed by Histowiz (Brooklyn, New York).
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![Generation and characterization of FCP351G iPSCs. (A) Sanger sequence of RECQL4 Exons 11-12 depicting the deletion found in FCP351 fibroblasts and verified by Sanger sequencing (see chromatogram) in FCP351G iPSCs. (B) Cell morphology (left panel) and alkaline phosphatase staining (right panel) of the FCP351G line. Scale bar, 250 μm (left) and 100 μm (right). (C) PCR detection of exogenous OCT4, SOX2, KLF4 and c-MYC in FCP351G iPSCs. (D) Mycoplasma PCR assay in FCP351G iPSCs.(E) Immunofluorescence staining of pluripotency factor NANOG and hESC surface markers (SSEA4 and TRA-1-81) in the FCP351G line. Scale bar, 75 μm. (F) qRT-PCR assay for the expression of endogenous pluripotency genes (NANOG, SOX2, OCT4, DPPA4, REX1, and TERT) in the FCP351G iPSCs. (G) A representative G-banded karyotype from iPSCs (FCP351G) showing 46, XX. (H) In vivo teratoma assay of the FCP351G iPSCs. Scale bar, 50 μm.](nihms-1516406-f0001){#F1}

###### 

Characterization and validation.

  Classification                      Test                                       Result                                                                                  Data
  ----------------------------------- ------------------------------------------ --------------------------------------------------------------------------------------- ---------------------------------------
  Morphology                          Photography                                Normal                                                                                  [Fig. 1](#F1){ref-type="fig"} panel B
  Phenotype                           Qualitative analysis immunocytochemistry   Positive staining for NANOG, SSEA and TRA-1-81                                          [Fig. 1](#F1){ref-type="fig"} panel E
                                      Quantitative analysis RT-qPCR              Expression of pluripotency markers equivalent or greater than H1 embryonic stem cells   [Fig. 1](#F1){ref-type="fig"} panel F
  Genotype                            Karyotype (G-banding) and resolution       46; XX, Resolution 400                                                                  [Fig. 1](#F1){ref-type="fig"} panel G
  Identity                            Microsatellite PCR (mPCR) OR               DNA Profiling not performed                                                             N/A
                                      STR analysis                               14 sites tested, all sites match                                                        data available with authors
  Mutation analysis (IF APPLICABLE)   Sequencing                                 Heterozygous                                                                            [Fig. 1](#F1){ref-type="fig"} panel A
                                      Southern Blot OR WGS                       N/A                                                                                     N/A
  Microbiology and virology           Mycoplasma                                 Negative                                                                                [Fig. 1](#F1){ref-type="fig"} panel D
  Differentiation potential           Teratoma formation                         Differentiation to all three germ layers confirmed by H&E Staining                      [Fig. 1](#F1){ref-type="fig"} panel H
  Donor screening (OPTIONAL)          N/A                                        N/A                                                                                     N/A
  Genotype additional info            N/A                                        N/A                                                                                     N/A
    (OPTIONAL)                        N/A                                        N/A                                                                                     N/A

###### 

Reagents details.

  Antibodies used for immunocytochemistry                                                             
  ----------------------------------------- ------------------------------------------------- ------- ----------------------------------------------------------------
  Pluripotency Markers                      Goat anti-NANOG                                   1:500   R and D Systems Cat\# AF1997 RRID:AB_355097
  Pluripotency Markers                      anti-SSEA4 PE-conjugated                          1:600   R and D Systems FA1435P-025
  Pluripotency Markers                      Mouse anti-TRA-1-85 Alexa Fluor 555-conjugated    1:600   R and D Systems Cat\# FAB3195A RRID:AB_663789
  Secondary antibodies                      Donkey Anti-Goat IgG (Alexa Fluor488 conjugate)   1:500   Jackson ImmunoResearch Labs Cat\# 705--545-003 RRID:AB_2340428

  ----------------------------------------------------------------------------------------
  Primers                                                 
  ------------------------------- ----------------------- --------------------------------
  PCR/Sequencing                  *RECQL4* Exons 11--12   CAGATTCGGGCAGCCCAGGTAC\
                                                          ACCCACCTGGTCTGTGTCCCTG

  Pluripotency Marker (qPCR)      *NANOG*                 TTTGTGGGCCTGAAGAAAACT\
                                                          AGGGCTGTCCTGAATAAGCAG

  Pluripotency Marker (qPCR)      *OCT4*                  AACCTGGAGTTTGTGCCAGGGTTT\
                                                          TGAACTTCACCTTCCCTCCAACCA

  Pluripotency Marker (qPCR)      *SOX2*                  AGAAGAGGAGAGAGAAAGAAAGGGAGAGA\
                                                          GAGAGAGGCAAACTGGAATCAGGATCAAA

  Pluripotency Marker (qPCR)      *DPPA4*                 GACCTCCACAGAGAAGTCGAG\
                                                          TGCCTTTTTCTTAGGGCAGAG

  Pluripotency Marker (qPCR)      *REX1*                  GCCTTATGTGATGGCTATGTGT\
                                                          ACCCCTTATGACGCATTCTATGT

  Pluripotency Marker (qPCR)      *TERT*                  TGAAAGCCAAGAACGCAGGGATG\
                                                          TGTCGAGTCAGCTTGAGCAGGAATG

  Housekeeping Genes (qPCR)       *GAPDH*                 CCACTCCTCCACCTTTGAC\
                                                          ACCCTGTTGCTGTAGCCA

  Sendai Virus Removal (RT-PCR)   *SeV*                   GGATCACTAGGTGATATCGAGC\
                                                          ACCAGACAAGAGTTTAAGAGATATGTATC

  Pluripotency Marker (RT-PCR)    *KOS*                   ATGCACCGCTACGACGTGAGCGC\
                                                          ACCTTGACAATCCTGATGTGG

  Pluripotency Marker (RT-PCR)    *KLF4*                  TTCCTGCATGCCAGAGGAGCCC\
                                                          AATGTATCGAAGGTGCTCAA

  Pluripotency Marker (qPCR)      *MYC*                   TAACTGACTAGCAGGCTTGTCG\
                                                          TCCACATACAGTCCTGGATGATGATG
  ----------------------------------------------------------------------------------------
